EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The urokinase receptor/uPAR is a major effector of p53 gain-of-function mutations in gemcitabine-treated pancreatic ductal adenocarcinoma

Carlotta Zampieri, Kourosh Kouhmareh, Parnian Sartipdolagh, Pardis Azmoon, Richard L Klemke, Steven L Gonias

Journal of Biological Chemistry · 2025

DOI: 10.1016/j.jbc.2025.110561 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Biological Chemistry, 2025. Verfasst von Carlotta Zampieri und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, University of California San Diego School of Medicine, La Jolla, California, USA. Hauptthemen laut MEDLINE: Carcinoma, Pancreatic Ductal, Deoxycytidine, Receptors, Urokinase Plasminogen Activator, Tumor Suppressor Protein p53. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, National Institutes of Health, National Heart Lung and Blood Institute Division of Intramural Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In pancreatic ductal adenocarcinoma (PDAC), chemotherapy may select for cancer cells with increased capacity for invasion and metastasis. The responsible mechanisms remain incompletely elucidated; however, TP53, which carries gain-of-function (GoF) mutations, has been implicated. PLAUR encodes a cellular receptor, uPAR, which promotes cancer invasion, metastasis, epithelial-mesenchymal transition (EMT), and resistance to chemotherapy. Mining TCGA showed that in PDAC, PLAUR expression is substantially increased and the extent of increase correlates with cancer stage. High PLAUR expression is associated with decreased overall, disease-free, and progression-free survival. PLAUR expression is increased in PDACs with TP53 GoF mutations. In PANC1 and MIA PaCa-2 PDAC cells, which express TP53 GoF mutations, gemcitabine treatment increased PLAUR expression, ERK1/2 activation, and ribosomal S6 kinase phosphorylation in surviving cells. The surviving cells also demonstrated increased migration and invasion. The increase in uPAR abundance was sustained and continued to increase after gemcitabine was withdrawn. Silencing TP53 blocked the gemcitabine-induced increase in uPAR abundance and the associated increases in ERK1/2 activation, cell migration, and invasion. Silencing EGFR did not affect uPAR-promoted ERK1/2 activation, despite the known ability of the EGF Receptor to collaborate with uPAR in activating cell signaling under select circumstances. scRNA-Seq of human PDACs showed that PLAUR expression is increased in specific clusters of malignant epithelial cells post-treatment. High PLAUR expression is associated with increased basal cell-like gene expression signatures, copy number instability, and EMT signatures. Mutated TP53-induced PLAUR expression represents a major pathway by which PDAC treatment may lead to chemotherapy resistance and increased cancer cell aggressiveness.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Pancreatic DuctalDeoxycytidineReceptors, Urokinase Plasminogen ActivatorTumor Suppressor Protein p53Pancreatic NeoplasmsGain of Function MutationAntimetabolites, AntineoplasticHumansGemcitabineCell Line, TumorCell MovementGene Expression Regulation, Neoplastic

Stichwörter der Autor:innen

cancer therapychemoresistancep53plasminogen activatorurokinase receptor

Substanzen

GemcitabineDeoxycytidineReceptors, Urokinase Plasminogen ActivatorTumor Suppressor Protein p53TP53 protein, humanPLAUR protein, humanAntimetabolites, Antineoplastic

Autor:innen und Institutionen

  • Department of Pathology, University of California San Diego School of Medicine, La Jolla, California, USA.
  • Department of Pathology, University of California San Diego School of Medicine, La Jolla, California, USA. Electronic address: sgonias@health.ucsd.edu.

Förderung

  • NHLBI NIH HHS
  • National Institutes of Health
  • National Heart Lung and Blood Institute Division of Intramural Research

Zitieren

APA

Zampieri, C., Kouhmareh, K., Sartipdolagh, P., Azmoon, P., Klemke, R. L., & Gonias, S. L. (2025). The urokinase receptor/uPAR is a major effector of p53 gain-of-function mutations in gemcitabine-treated pancreatic ductal adenocarcinoma. Journal of Biological Chemistry. https://doi.org/10.1016/j.jbc.2025.110561

Vancouver

Zampieri C, Kouhmareh K, Sartipdolagh P, Azmoon P, Klemke RL, Gonias SL. The urokinase receptor/uPAR is a major effector of p53 gain-of-function mutations in gemcitabine-treated pancreatic ductal adenocarcinoma. Journal of Biological Chemistry. 2025. doi:10.1016/j.jbc.2025.110561

BibTeX
@article{Zampieri2025,
  author = {Zampieri, Carlotta and Kouhmareh, Kourosh and Sartipdolagh, Parnian and Azmoon, Pardis and Klemke, Richard L and Gonias, Steven L},
  title = {The urokinase receptor/uPAR is a major effector of p53 gain-of-function mutations in gemcitabine-treated pancreatic ductal adenocarcinoma},
  journal = {Journal of Biological Chemistry},
  year = {2025},
  doi = {10.1016/j.jbc.2025.110561}
}
Kostenlos starten →